Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in oral drug delivery platforms, announced today that it will attend the BIO International Convention from June 22-25 in San Diego, CA. The company’s attendance at last year’s 2025 BIO convention served as a catalyst for its greatly expanded business development program that is now starting to deliver positive results and which Lexaria intends to build upon at this year’s conference.
“We are experiencing record-high levels of business development and collaboration interest in our DehydraTECH platform, even before the upcoming BIO conference,” said Richard Christopher, CEO of Lexaria Bioscience. “New business relationships require intense energy and scientific evaluation from both prospective partners to discover the best fit possible. We are working tirelessly in this regard with the intent of generating positive developments that we can publicly discuss.”
BIO is the largest convention of its kind, with over 20,000 attendees expected from all corners of the global pharmaceutical and biotechnology industries, as well as their supporting sectors such as investors and finance professionals. The conference is focused on intra-industry collaborations and meetings, with over 66,000 partnering meetings having taken place at the 2025 conference. Lexaria has already begun reserving meetings and will be fully booked for the event given the strong industry interest in its proprietary DehydraTECH drug delivery platform.
BIO is only the latest example of a multi-faceted business development program that Lexaria quietly launched in order to inform prospective business partners of the benefits available through DehydraTECH. Although confidential information, by its nature, cannot be publicly disclosed, Lexaria’s business development program has already generated a number of collaborative and potential business partnering discussions with a wide range of companies from innovative smaller biotech developers to well-known global pharmaceutical giants.
The company’s DehydraTECH platform is a patented drug delivery formulation and processing technology that improves the way drugs enter the bloodstream through oral delivery. It has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide.
While Lexaria’s business development program has already developed a number of ongoing discussions, it continues to develop additional early-stage leads. The company intends to thoroughly evaluate each potential relationship, large and small, and ultimately only pursue those that are in the best interests of its shareholders. Additional information will be made available when appropriate.
The importance of this announcement lies in the potential for Lexaria’s DehydraTECH platform to transform oral drug delivery across the pharmaceutical industry, offering improved efficacy and reduced side effects. The company’s expanded business development efforts, catalyzed by last year’s BIO convention, are now yielding tangible interest from both small biotech firms and global pharmaceutical giants. This could lead to partnerships that accelerate the development and commercialization of drugs using DehydraTECH, impacting patients and the healthcare industry.
For more information about Lexaria Bioscience Corp. and DehydraTECH, visit www.lexariabioscience.com.
